Skip to content

Faculty profile

Aymeric Ravel-Chapuis

Back to faculty
Assistant ProfessorSchool of Pharmaceutical SciencesUniversity of Ottawa

Research

Read how they describe their research on their University of Ottawa profile.

Latest papers

  • A bitter melon natural compound ameliorates the myotonic dystrophy type 1 skeletal muscle phenotype in a sex-specific manner.

    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026

  • Exercise mimetics as unexplored therapeutics for treating depression.

    Molecular psychiatry · 2026

  • Disruptions of cell signaling pathways in myotonic dystrophy type 1 skeletal muscle, their pathogenic impact, and potential for combinatorial therapeutics.

    The Journal of biological chemistry · 2026 · first author

All 28 publications

Latest funding

  • NMD4C: the neuromuscular network for Canada

    CIHR · 2023 · Co-investigator

    $1,000,000
  • Pharmacologic and RNAi Screens for Myotonic Dystrophy Type 1 foci modulators; towards Novel DM1 therapeutic approaches

    CIHR · 2018 · Co-investigator

    $481,950
All 2 grants and awards

Profile data last refreshed on September 25, 2026 from the university directory, publication records and CIHR, NSERC and SSHRC funding.

Something wrong or missing on this profile? Suggest a correction